- Home
- APLS vs ACAD Comparison
APLS vs ACAD Comparison
Compare APLS & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- ACAD
- Stock Information
- Founded
- APLS 2009
- ACAD 1993
- Country
- APLS United States
- ACAD United States
- Employees
- APLS N/A
- ACAD N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- ACAD Health Care
- Exchange
- APLS Nasdaq
- ACAD Nasdaq
- Market Cap
- APLS 3.3B
- ACAD 2.8B
- IPO Year
- APLS 2017
- ACAD 2004
- Fundamental
- Price
- APLS $18.20
- ACAD $14.73
- Analyst Decision
- APLS Buy
- ACAD Buy
- Analyst Count
- APLS 18
- ACAD 16
- Target Price
- APLS $45.59
- ACAD $23.93
- AVG Volume (30 Days)
- APLS 2.8M
- ACAD 1.8M
- Earning Date
- APLS 05-06-2025
- ACAD 05-07-2025
- Dividend Yield
- APLS N/A
- ACAD N/A
- EPS Growth
- APLS N/A
- ACAD N/A
- EPS
- APLS N/A
- ACAD 1.36
- Revenue
- APLS $781,367,000.00
- ACAD $957,797,000.00
- Revenue This Year
- APLS $12.71
- ACAD $13.07
- Revenue Next Year
- APLS $20.93
- ACAD $9.88
- P/E Ratio
- APLS N/A
- ACAD $10.83
- Revenue Growth
- APLS 97.02
- ACAD 31.85
- 52 Week Low
- APLS $17.49
- ACAD $13.40
- 52 Week High
- APLS $53.06
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- APLS 28.14
- ACAD 38.07
- Support Level
- APLS $18.00
- ACAD $14.34
- Resistance Level
- APLS $19.71
- ACAD $15.18
- Average True Range (ATR)
- APLS 1.63
- ACAD 0.80
- MACD
- APLS -0.16
- ACAD -0.02
- Stochastic Oscillator
- APLS 10.98
- ACAD 38.22
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.